看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。9 p, ^4 C2 I n5 N2 [8 r2 q
+ ~, G! z- m) x5 `' P: G9 V
+ p! |% F, w& M4 F* h9 ]/ OCurrently available feasibility data for possible combination strategies. 4 a! w7 N+ R9 L+ R
————————————————————————————————
( \5 [! n) `' y- f* R8 X0 xCombination Feasibility according to preliminary data
4 W6 k2 \0 A+ z1 q5 N. e——————————————————————————————————
, }( L1 _# P u/ u; nBevacizumab + sorafenib Yes, reduced dose % H6 Z- c8 R+ i }
Bevacizumab + sunitinib† No
2 d v. X+ n6 iBevacizumab + temsirolimus Yes 2 E- V+ J5 I) r+ E( m+ S2 q4 ]
Bevacizumab + everolimus Yes + q& H+ ]1 x g$ F
Sorafenib + sunitinib ?
# O- j- u* N3 Y0 D, HSorafenib + temsirolimus Yes, reduced dose
; `, l+ ~ V$ ^, ISorafenib + everolimus Yes, reduced dose
. A6 w# `) X9 m( gSunitinib + temsirolimus† No
- C- P0 Y3 Q: mSunitinib + everolimus ?
) C+ r I! c5 i9 r9 i* t' E8 iTemsirolimus + everolimus ? h/ { k! x9 G; S6 S7 a
————————————————————
+ Y r0 P7 B! H: p' _†Led to US FDA warning.# a0 p$ i2 K7 M! w$ c0 O6 A
?: As yet unattempted combination.' W' Z$ P: @: }3 J, {, O/ J
|